Compare WYETH LTD with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs FRESENIUS KABI ONCO. - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD FRESENIUS KABI ONCO. WYETH LTD/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 27.7 22.1 125.3% View Chart
P/BV x 5.3 3.1 171.8% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    WYETH LTD
Mar-13
FRESENIUS KABI ONCO.
Mar-13
WYETH LTD/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,044176 593.4%   
Low Rs81879 1,042.0%   
Sales per share (Unadj.) Rs298.637.7 792.3%  
Earnings per share (Unadj.) Rs57.25.1 1,123.9%  
Cash flow per share (Unadj.) Rs58.46.7 868.8%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.542.5 586.4%  
Shares outstanding (eoy) m22.72158.23 14.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.4 92.4%   
Avg P/E ratio x16.325.0 65.1%  
P/CF ratio (eoy) x15.918.9 84.2%  
Price / Book Value ratio x3.73.0 124.8%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,15720,135 105.1%   
No. of employees `0000.51.2 42.7%   
Total wages/salary Rs m400703 56.9%   
Avg. sales/employee Rs Th13,787.45,176.2 266.4%   
Avg. wages/employee Rs Th813.0610.4 133.2%   
Avg. net profit/employee Rs Th2,643.3699.6 377.8%   
INCOME DATA
Net Sales Rs m6,7835,963 113.8%  
Other income Rs m35318 1,958.9%   
Total revenues Rs m7,1365,981 119.3%   
Gross profit Rs m1,6171,430 113.1%  
Depreciation Rs m27258 10.3%   
Interest Rs m6-26 -21.2%   
Profit before tax Rs m1,9381,216 159.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5-68 7.5%   
Tax Rs m632342 184.7%   
Profit after tax Rs m1,301806 161.4%  
Gross profit margin %23.824.0 99.4%  
Effective tax rate %32.628.1 115.9%   
Net profit margin %19.213.5 141.9%  
BALANCE SHEET DATA
Current assets Rs m6,9845,102 136.9%   
Current liabilities Rs m2,0562,385 86.2%   
Net working cap to sales %72.645.6 159.5%  
Current ratio x3.42.1 158.8%  
Inventory Days Days99150 66.2%  
Debtors Days Days24113 21.1%  
Net fixed assets Rs m2445,148 4.7%   
Share capital Rs m227158 143.6%   
"Free" reserves Rs m5,4416,556 83.0%   
Net worth Rs m5,6686,732 84.2%   
Long term debt Rs m25952 2.6%   
Total assets Rs m7,90110,388 76.1%  
Interest coverage x353.3-45.8 -771.8%   
Debt to equity ratio x00.1 3.1%  
Sales to assets ratio x0.90.6 149.6%   
Return on assets %16.57.5 220.2%  
Return on equity %22.912.0 191.7%  
Return on capital %34.014.6 233.1%  
Exports to sales %0.274.5 0.3%   
Imports to sales %36.324.8 146.7%   
Exports (fob) Rs m154,441 0.3%   
Imports (cif) Rs m2,4651,477 166.9%   
Fx inflow Rs m155,298 0.3%   
Fx outflow Rs m2,6771,772 151.1%   
Net fx Rs m-2,6623,525 -75.5%   
CASH FLOW
From Operations Rs m9231,274 72.5%  
From Investments Rs m317-1,204 -26.3%  
From Financial Activity Rs m-481-196 245.3%  
Net Cashflow Rs m759-126 -601.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 81.0 63.1%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 7.2 9.6 75.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 9.1 334.1%  
Shareholders   21,978 42,599 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Climbs 975 Points Up; FMCG Stocks Fuel the Rally(09:30 am)

Asian share markets started higher on Monday on hopes of an interim Sino-US tariff deal after the two countries described their talks as "productive" and "constructive".

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS